# Early Evaluation of Chemosensitivity for Low/Intermediated-risk Mid-low Stage II/III Rectal Cancer

> **NCT03666442** · PHASE2 · COMPLETED · sponsor: **West China Hospital** · enrollment: 61 (actual)

## Conditions studied

- Rectal Cancer

## Interventions

- **DRUG:** XELOX

## Key facts

- **NCT ID:** NCT03666442
- **Lead sponsor:** West China Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-06-01
- **Primary completion:** 2020-01-01
- **Final completion:** 2022-01-01
- **Target enrollment:** 61 (ACTUAL)
- **Last updated:** 2022-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03666442

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03666442, "Early Evaluation of Chemosensitivity for Low/Intermediated-risk Mid-low Stage II/III Rectal Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03666442. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*